The Okuvision Story
From the beginnings to today: how Okuvision co-developed TES therapy, established it in clinical practice, and built care pathways across Europe.
From Idea to Foundation
Okuvision GmbH was established to provide individuals with degenerative retinal diseases (including RP) a treatment option based on the latest advancements in technology and research – with the clear goal: “Preserving Vision.”
At the end of 2007, Okuvision was founded as a subsidiary of Retina Implant AG and is now an independent company; its headquarters are in Kusterdingen in the Tübingen/Reutlingen Technology Park (TTR). Retinal electrical stimulation (TES) was developed together with experts from the Department of Ophthalmology at Tübingen University Hospital.
Why this approach? Because it is non-invasive, can be integrated into everyday life, and is carried out under medical supervision. From the outset, the key question was how to combine safety, efficacy, and user-friendliness in a system that can be used at home. Prototypes, user workshops, and feedback from clinics paved the way to the first production-ready system.
Technological Milestones
At the heart of this is the OkuStim® system, whose components are continuously being further developed. New scientific findings are incorporated on an ongoing basis; at the same time, Okuvision maintains close dialogue with patients, opticians, and ophthalmologists to strengthen the benefits and everyday usability of the therapy.
For us, technology is not an end in itself: key guiding principles are ease of use, clear feedback during the session (visual/acoustic), and standardized procedures for weekly use. Equally important: robust materials, transparent maintenance, and consumer-friendly supply of accessories—so that the therapy remains predictable, affordable, and safe.
Clinical Evidence andRegulatory Approval Steps
Since 2011, several studies involving RP patients have demonstrated the safety and efficacy of electrical stimulation; follow-up studies confirmed the results. OkuStim® therapy is approved and available as an externally applied therapy for RP based on clinical studies.
For product approval, Okuvision operates a certified quality management system (QMS); the CE mark as a Class IIa medical device was first granted in 2014.
Why does it take so much effort? Degenerative retinal diseases progress slowly and vary from person to person. Efficacy can therefore only be demonstrated using suitable endpoints and over longer periods of time—e.g., in visual field progression or in patient-relevant outcome measures. In parallel, Good Clinical Practice standards, risk management, and usability tests safeguard care provision.
Today and Tomorrow: Expanding Care, Advancing Research
Okuvision supplies patients in many European countries with the OkuStim® system and continuously expands its network of qualified ophthalmologists, centers of excellence, and opticians. The work is guided by evidence, quality, and service—with reliable processes for inquiries from patients, physicians, and care partners.
What does that mean in practice?
- Better support: curated information for those affected and their families—from diagnosis to training
- Safe use: training by specialist staff, individualized parameters, and regular check-ups
- Stay connected: exchange with patient organizations, clinics, and providers to strengthen care regionally and across borders
- Think ahead: collaboration with research partners on mechanisms, dosing questions, and care models so that the therapy has a sustainable impact in everyday life
Milestones ofOkuvision
Okuvision has already been on a journey. Below you will find an overview.
2007
End of 2007 – Founded (subsidiary of Retina Implant AG) – now an independent company; headquarters: Kusterdingen.
2011
From 2011 – Clinical studies with RP patients demonstrate efficacy & safety; further studies follow.
2014
2014 – CE mark (Class IIa) for the OkuStim® system within a certified QMS.
2025
2025 – Approval of OkuStim® 2.
Today
Today – Europe-wide care provision via a growing network; continuous further development of the components.
Insights into Therapy,Research & Company
Interview: Founding & Vision
Alfred Stett on the journey from neurostimulation to evidence-based care—and what drives Okuvision.